Details for Patent: 6,017,928
✉ Email this page to a colleague
| Title: | Retroviral protease inhibiting compounds |
| Abstract: | A retroviral protease inhibiting compound of the formula: ##STR1## is disclosed. |
| Inventor(s): | Kempf; Dale J. (Libertyville, IL), Norbeck; Daniel W. (Crystal Lake, IL), Sham; Hing Leung (Gurnee, IL), Zhao; Chen (Gurnee, IL), Sowin; Thomas J. (Grayslake, IL), Reno; Daniel S. (Kenosha, WI), Haight; Anthony R. (Park City, IL) |
| Assignee: | Abbott Laboratories (Abbott Park, IL) |
| Filing Date: | Oct 06, 1997 |
| Application Number: | 08/944,351 |
| Claims: | 1. A method for treating a retroviral infection in a mammal comprising administering to said mammal: (a) an effective amount of a first retroviral protease inhibitor; and (b) an effective amount of a second retroviral protease inhibitor wherein said second retroviral protease inhibitor is effective against at least one retroviral strain that is resistant to said first retroviral protease inhibitor; wherein said first retroviral protease inhibitor is (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)ca rbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-dipheny l-3-hydroxyhexane and said second retroviral protease inhibitor is N-tert-Butyl decahydro-2-(2(R)-hydroxy-4-phenyl-3(S)-((N-(2-quinolylcarbonyl)-L-asparag inyl)amino)butyl)-(4aR,8aS)-isoquinoline-3(S)-carboxamide. 2. A method for treating a retroviral infection in a mammal comprising administering to said mammal: (a) an effective amount of a first retroviral protease inhibitor; and (b) an effective amount of a second retroviral protease inhibitor wherein said second retroviral protease inhibitor is effective against at least one retroviral strain that is resistant to said first retroviral protease inhibitor; wherein said first retroviral protease inhibitor is N-tert-Butyl decahydro-2-(2(R)-hydroxy-4-phenyl-3(S)-((N-(2-quinolylcarbonyl)-L-asparag inyl)amino)butyl)-(4aR,8aS)-isoquinoline-3(S)-carboxamide and said second retroviral protease inhibitor is (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)ca rbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-dipheny l-3-hydroxyhexane. 3. A method for treating a retroviral infection in a patient comprising: (a) selecting two retroviral protease inhibitors wherein a second selected retroviral protease inhibitor is effective against at least one retroviral strain that is resistant to a first selected retroviral protease inhibitor; and (b) administering to said patient an effective amount of each said first and second selected inhibitors; wherein said first retroviral protease inhibitor is (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)ca rbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-dipheny l-3-hydroxyhexane and said second retroviral protease inhibitor is N-tert-Butyl decahydro-2-(2(R)-hydroxy-4-phenyl-3(S)-((N-(2-quinolylcarbonyl)-L-asparag inyl)amino)butyl)-(4aR,8aS)-isoquinoline-3(S)-carboxamide. 4. A method for treating a retroviral infection in a patient comprising: (a) selecting two retroviral protease inhibitors wherein a second selected retroviral protease inhibitor is effective against at least one retroviral strain that is resistant to a first selected retroviral protease inhibitor; and (b) administering to said patient an effective amount of each said first and second selected inhibitors; wherein said first retroviral protease inhibitor is N-tert-Butyl decahydro-2-(2(R)-hydroxy-4-phenyl-3(S)-((N-(2-quinolylcarbonyl)-L-asparag inyl)amino)butyl)-(4aR,8aS)-isoquinoline-3(S)-carboxamide and said second retroviral protease inhibitor is (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)ca rbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-dipheny l-3-hydroxyhexane. |
